Mark Gardner
Impact in
- Pharmacology top 1%
- Pharmacogenetics and Drug Metabolism
- Antibiotics Pharmacokinetics and Efficacy
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
Papers in
- Pharmacology 15
- Pharmacogenetics and Drug Metabolism 15
- Antibiotics Pharmacokinetics and Efficacy 2
- Oncology 7
- Cancer Immunotherapy and Biomarkers 6
- Co-authors
- Jerome J. Schentag (4 shared papers)William J. Jusko (5 shared papers)Donald M. Hilligoss (5 shared papers)Antoinette Mangione (2 shared papers)John W. Vance (1 shared paper)Jeffrey R. Koup (1 shared paper)Robert A. Blum (2 shared papers)Anthony M. Yurchak (2 shared papers)
- Journals
- The Journal of Clinical Pharmacology (5 papers)Journal for ImmunoTherapy of Cancer (4 papers)Clinical Pharmacology & Therapeutics (4 papers)Oncotarget (3 papers)Journal of Pharmaceutical Sciences (2 papers)
- Partner nations
- United StatesFranceSpain
In The Last Decade
Mark Gardner
33 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 88
- Pharmacology 413
- Oncology 297
- Infectious Diseases 206
- Pharmacology 145
- Pharmaceutical Science 68
Countries citing papers authored by Mark Gardner
This map shows the geographic impact of Mark Gardner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Gardner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Gardner more than expected).
Fields of papers citing papers by Mark Gardner
This network shows the impact of papers produced by Mark Gardner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Gardner. The network helps show where Mark Gardner may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Gardner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 34 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1979 | 213 | |
| 2 | 1991 | 149 | |
| 3 | 1978 | 146 | |
| 4 | 2018 | 124 | |
| 5 | 1991 | 100 | |
| 6 | 1991 | 96 | |
| 7 | 2019 | 78 | |
| 8 | 2019 | 77 | |
| 9 | 2017 | 66 | |
| 10 | 1991 | 60 | |
| 11 | 2014 | 56 | |
| 12 | 1993 | 46 | |
| 13 | 1995 | 43 | |
| 14 | 2016 | 38 | |
| 15 | 1988 | 31 | |
| 16 | 1997 | 29 | |
| 17 | 2006 | 24 | |
| 18 | 2018 | 18 | |
| 19 | 2019 | 18 | |
| 20 | 2006 | 17 |
About Mark Gardner
Mark Gardner is a scholar working on Pharmacology, Oncology, Endocrinology, Diabetes and Metabolism, Pharmacology and Pharmaceutical Science, having authored 34 papers that have together received 1.6k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (15 papers), Cancer Immunotherapy and Biomarkers (6 papers), Menopause: Health Impacts and Treatments (4 papers), Drug Solubulity and Delivery Systems (2 papers), Antifungal resistance and susceptibility (2 papers), Cancer Genomics and Diagnostics (2 papers), Antibiotics Pharmacokinetics and Efficacy (2 papers) and Pharmaceutical studies and practices (2 papers). The work is most often cited by research in Pharmacology (413 citations), Oncology (297 citations), Infectious Diseases (206 citations), Pharmacology (145 citations) and Pharmaceutical Science (68 citations). Mark Gardner has collaborated with scholars based in United States, France and Spain. Frequent co-authors include Jerome J. Schentag, William J. Jusko, Donald M. Hilligoss, Antoinette Mangione, John W. Vance, Jeffrey R. Koup, Robert A. Blum, Anthony M. Yurchak, John H. Clark and John H. Wilton. Their work appears in journals such as The Journal of Clinical Pharmacology, Journal for ImmunoTherapy of Cancer, Clinical Pharmacology & Therapeutics, Oncotarget and Journal of Pharmaceutical Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.